Maxx Chatsko

Maxx Chatsko


Maxx has been a contributor to since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles

chalkboard stock down pink

Here's Why Neoleukin Therapeutics Dropped Today

The development-stage drug company announced the pricing of a public offering of common stock.

534 eye drops

Is Aerie Pharmaceuticals a Buy?

Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?

046 dna model

Is Iovance Biotherapeutics a Buy?

After rumors swirled about a potential acquisition, it now appears the biopharma is transitioning to commercial operations as a standalone company.

arrow up shelves

Here's Why BioNTech Jumped Today

The German biopharma announced a $250 million private investment.

paper airplanes rising

Here's Why Athersys Stock Is Soaring Today

The stem cell stock jumped after a major Wall Street firm initiated coverage, but there's a catch.

297 head in sand

Is Wall Street Wrong About Mesoblast?

The cell therapy developer expects to have clinical data for its COVID-19 treatment soon. Will it deliver a historic success or continue the poor track record of stem cell candidates?

236 worried investor

Shares of Renewable Energy Group Slide After Revising Q2 Outlook Lower

The biomass-based diesel leader is suffering from both poor market conditions and embarrassing errors in its previous guidance.

multiple lines up

Here's Why Agenus Stock Jumped Higher Today

The development-stage biopharma delivered two encouraging updates.

coins in hands stock up

Silver Stocks Jump as Confirmed COVID-19 Cases Rise

Investors are betting precious metals will prove resilient through the ongoing economic slowdown.

dude tossing stacks

Invitae Surges on $1.4B Acquisition of ArcherDX

The genetic testing company pulled the trigger on its largest acquisition yet.

funky arrows rising

Here's Why Selecta Biosciences Stock Is Soaring Today

A bullish article is sending shares higher.

multiple lines down

Here's Why IDEAYA Biosciences Lost Nearly 23% Today

The development-stage drug developer is selling common stock to raise cash. It's a wise move.

076 arrow dude getty

Here's Why PolyMet Mining Is Soaring This Week

The development-stage mining company is one step closer to starting operations at a long-delayed project in Minnesota.

stock down erased chalkboard

Here's Why Selecta Biosciences Is Tumbling Today

A licensing deal for a late-stage asset failed to impress Wall Street. One analyst went as far as downgrading the biopharma stock.

blocks arrows rising

2 Top Small-Cap Stocks to Buy Right Now

Volatile stock market or not, these two drug developers are well positioned for long-term success.

stock down angry fist

Here's Why Alliance Resource Partners Fell as Much as 13.5% Today

The Fed thinks the economy will take more time to recover than Wall Street was expecting, which is bad news for this coal stock.

stock down finger

Here's Why Invitae Fell as Much as 10.1% Today

The growth stock is an easy target in a volatile market.

chalkboard stock down pink

Here's Why Renewable Energy Group Dropped Over 10% Today

The small-cap stock hit an all-time high earlier this month, but gloomy economic outlooks have investors rethinking the company's valuation.

arrow up shelves

New Gold Rises as Much as 12.9% on Series of Financing Deals

The gold miner is making moves to improve its near-term financial flexibility.

business growth

Here's Why Albemarle Gained 24.6% in May

The world's leading lithium producer benefitted from rising confidence about the pace of a possible economic recovery.